Accumulating evidence indicates that epigenetic events undergo deregulation in various cancer types, playing crucial roles in tumor development. Among the epigenetic factors involved in the epigenetic remodeling of chromatin, the chromodomain helicase DNA-binding protein (CHD) family frequently exhibits gain- or loss-of-function mutations in distinct cancer types. Therefore, targeting CHD remodelers holds the potential for antitumor treatment. In this review, we discuss epigenetic regulations of cancer development. We emphasize proteins in the CHD family, delving deeply into the intricate mechanisms governing their functions. Additionally, we provide an overview of current therapeutic strategies targeting CHD family members in preclinical trials. We further discuss the promising approaches that have demonstrated early signs of success in cancer treatment.

中文翻译：

---

靶向 CHD 蛋白家族在癌症中的治疗潜力


越来越多的证据表明，表观遗传事件在各种癌症类型中发生失调，在肿瘤发展中发挥着至关重要的作用。在参与染色质表观遗传重塑的表观遗传因素中，染色质解旋酶 DNA 结合蛋白 (CHD) 家族经常在不同的癌症类型中表现出功能获得或丧失的突变。因此，针对 CHD 重塑者具有抗肿瘤治疗的潜力。在这篇综述中，我们讨论了癌症发展的表观遗传调控。我们强调 CHD 家族中的蛋白质，深入研究控制其功能的复杂机制。此外，我们还概述了临床前试验中针对先心病家族成员的当前治疗策略。我们进一步讨论了在癌症治疗中已显示出成功的早期迹象的有前景的方法。